Hormone therapy for menstrual-associated migraine: pros and cons
https://doi.org/10.14412/2074-2711-2022-1-69-75
Abstract
About 60% of women report menstrual-associated migraine attacks, characterized by a higher intensity and duration and more pronounced treatment resistance. Often, preventive treatment with drugs aimed to relieve menstrual attacks – non-steroidal anti-inflammatory drugs and triptans – is difficult in these patients due to a high risk of medication-overuse headache. In addition, due to a hormonal trigger – a perimenstrual decrease in estrogen – the effect of hormonal contraceptives on migraine attacks has been studied for a long time. This article discusses the results of studies indicating the successful administration of specific hormone therapy regimens, especially in patients with concomitant gynecological pathology or in patients using these drugs for contraception.
About the Authors
E. A. Kiryanova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine,
11, Rossolimo St., Build. 1, Moscow 119021
G. R. Тabeeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine,
11, Rossolimo St., Build. 1, Moscow 119021
References
1. Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Ways of optimizing the management of patients with migraine in Russia (resolution of the council of experts). Zhurnal nevrologii i psikhiatrii imeni SS Korsakova. 2018;118(6):124-8. doi: 10.17116/jnevro201811861124 (In Russ.).
2. Borsook D, Erpelding N, Lebel A. Sex and the migraine brain. Neurobiol Dis. 2014 Aug;68:200-14. doi: 10.1016/j.nbd.2014.03.008. Epub 2014 Mar 21.
3. Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr. 2015 Feb;20(1):48-59. doi: 10.1017/S1092852914000480. Epub 2014 Sep 29.
4. Kareva EN, Oleynikova OM, Panov VO, et al. Estrogens and brain. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2012;67(2):48-59 (In Russ.).
5. Wilson H, Tashani O. Hormonal contraceptive pill effect on pain sensitivity response. Int J Clin Exp Physiol. 2016;3(4):166-9. doi: 10.4103/2348-8832.196894
6. Martelletti P, Guglielmetti M. Approaching the appropriate pharmacotherapy of menstrual migraine. Expert Rev Neurother. 2020 Jan;20(1):1-2. doi: 10.1080/14737175.2020.1693265. Epub 2019 Nov 18.
7. Sacco S, Merki-Feld GS, Aegidius KL, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018 Aug 31;19(1):76. doi: 10.1186/s10194-018-0896-5
8. Ekusheva EV, Karpova MI, Osipova VV. Hormonal contraceptives and the risk of ischemic stroke in women with migraine: a new international consensus. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):11- 5. doi: 10.14412/2074-2711-2019-3-11-15 (In Russ.).
9. MacGregor EA. Migraine management during menstruation and menopause. Continuum (Minneap Minn). 2015 Aug;21(4 Headache):990-1003. doi: 10.1212/CON.0000000000000196
10. Nappi RE. Hormonally Related Headaches. In: Berga S, Genazzani A, Naftolin F, Petraglia F, eds. Menstrual Cycle Related Disorders. Switzerland: Springer; 2019. P. 93-100. doi: 10.1007/978-3-030-14358-9
11. O'Neal MA, Mittal LP, eds. Neurology and Psychiatry of Women: A Guide to Genderbased Issues in Evaluation, Diagnosis, and Treatment. Switzerland: Springer; 2019. doi: 10.1007/978-3-030-04245-5_4
12. Peng K-P, May A. Oral contraceptive use and its association with symptomatology in migraine patients. Cephalal Rep. 2019;2(5):1- 6. doi: 10.1177/2515816319856007
13. Dalton K. Migraine and oral contraceptives. Headache. 1976 Jan;15(4):247-51. doi: 10.1111/j.1526-4610.1976.he1504247.x
14. McKenna R. Increasing use of long-acting contraception in primary care. Primary Health Care. 2018. doi: 10.7748/phc.2018.e1410
15. Coffee AL, Sulak PJ, Hill AJ, et al. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Women's Health (Larchmt). 2014 Apr;23(4):310-7. doi: 10.1089/jwh.2013.4485. Epub 2014 Jan 22.
16. De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011 Oct;96(4):917-20. doi: 10.1016/j.fertnstert.2011.07.1089. Epub 2011 Aug 16.
17. Nappi RE, Terreno E, Sances G, et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013 Sep;88(3):369-75. doi: 10.1016/j.contraception.2013.02.001. Epub 2013 Feb 28.
18. Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004 Sep;97(9):819-22. doi: 10.1097/01.SMJ.0000129924.15619.D9
19. MacGregor EA, Hackshaw A. Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebocontrolled pilot study using natural oestrogen supplements. J Fam Plann Reprod Health Care. 2002 Jan;28(1):27-31. doi: 10.1783/147118902101195974
20. LaGuardia KD, Fisher AC, Bainbridge JD, et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril. 2005 Jun;83(6):1875-7. doi: 10.1016/j.fertnstert.2004.12.048
21. Calhoun A, Ford S, Pruitt A. The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache. 2012 Sep;52(8):1246-53. doi: 10.1111/j.1526-4610.2012.02211.x. Epub 2012 Jul 12.
22. DeLignieres B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous estradiol. Br Med J (Clin Res Ed). 1986 Dec 13;293(6561):1540. doi: 10.1136/bmj.293.6561.1540
23. Dennerstein L, Morse C, Burrows G, et al. Menstrual migraine: a double blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988 Jun;2(2):113-20. doi: 10.3109/09513598809023619
24. MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006 Dec 26;67(12):2159-63. doi: 10.1212/01.wnl.0000249114.52802.55
25. Almen-Christensson A, Hammar M, Lindh-Astrand L, et al. Prevention of menstrual migraine with perimenstrual transdermal 17-βestradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril. 2011 Aug;96(2):498-500.e1. doi: 10.1016/j.fertnstert.2011.05.089. Epub 2011 Jun 24.
26. Guidotti M, Mauri M, Barilla C, et al. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Heachache Pain. 2007 Oct;8(5):283-8. doi: 10.1007/s10194-007-0417- 4. Epub 2007 Oct 23.
27. Pradalier A, Vincent D, Beaulieu P, et al. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. In: Rose F, editor. New advances in headache research. London: Smith-Gordon; 1994. P. 129-32.
28. Smite VG, van der Meer YG, Pfeil JPJM, et al. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994 Feb;34(2):103-6. doi: 10.1111/j.1526-4610.1994.hed3402103.x
29. Magos A, Zilkha KJ, Studd JW. Treatment of menstrual migraine by oestradiol implants. J Neurol Neurosurg Psychiatry. 1983 Nov;46(11):1044-6. doi: 10.1136/jnnp.46.11.1044
30. Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017 May;216(5):489.e1-489.e7. doi: 10.1016/j.ajog.2016.12.019. Epub 2016 Dec 26.
31. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. BMJ. 1999 Jan 2;318(7175):13-8. doi: 10.1136/bmj.318.7175.13
32. MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke. 2007 Sep;38(9):2438-45. doi: 10.1161/STROKEAHA.107.488395. Epub 2007 Aug 9.
33. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995 Apr 1;310(6983):830-3. doi: 10.1136/bmj.310.6983.830
34. Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women. Associated risk factors. JAMA. 1975 Feb 17;231(7):718-22. doi: 10.1001/jama.1975.03240190022010
35. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke. 1998 Nov;29(11):2277-84. doi: 10.1161/01.str.29.11.2277
36. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol. 1995 Feb;102(2):153-9. doi: 10.1111/j.1471-0528.1995.tb09070.x
37. Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic stroke and active migraine. Neurology. 2001 Nov 27;57(10):1805-11. doi: 10.1212/wnl.57.10.1805
38. Fruzzetti F, Cagnacci A. Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives? Open Access J Contracept. 2018 Nov 8;9:75-9. doi: 10.2147/OAJC.S179673
39. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016 Oct;94(4):328-39. doi: 10.1016/j.contraception.2016.06.010. Epub 2016 Jun 22.
40. Sacco S, Merki-Feld GS, Aegidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017 Oct 30;18(1):108. doi: 10.1186/s10194-017-0815-1. Erratum in: J Headache Pain. 2018 Sep 10;19(1):81.
41. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012 Apr;13(3):177-89. doi: 10.1007/s10194-012-0424-y. Epub 2012 Feb 26.
42. Vetvik KG, MacGregor EA, Lundqvist C, Russell MB. Contraceptive-induced amenorrhoea leads to reduced migraine frequency in women with menstrual migraine without aura. J Headache Pain. 2014 May 17;15(1):30. doi: 10.1186/1129-2377-15-30
Review
For citations:
Kiryanova EA, Тabeeva GR. Hormone therapy for menstrual-associated migraine: pros and cons. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):69-75. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-69-75
Views:
732
Email this article 